CSL Research Acceleration Initiative: Seeking Expressions of Interest from Research Organisations
CSL is a leading global biotechnology company committed to developing and delivering innovative biotherapies to improve the lives of people with serious and life-threatening medical conditions.
CSL’s Research Acceleration Initiative aims to accelerate discovery of innovative biotherapies through partnerships between CSL and global research organisations. These partnerships provide funding and access to industry experts for scientists working on novel biotherapeutic strategies in CSL’s therapeutic areas.
The 2026 Research Acceleration Initiative will focus on innovative research projects that address unmet medical needs and are aligned with CSL’s Therapeutic Areas.
REGISTER YOUR RESEARCH ORGANISATION
Business Development (BD) and Commercialisation representatives from research organisations (universities, medical research institutes, hospitals) and companies (start-ups, biotechs) are invited to register their organisation’s interest to participate in the 2026 Research Acceleration Initiative before 12th December 2025.
NOMINATE YOUR PRIMARY CONTACT
CSL requests that each research organisation and company nominate one BD or Commercialisation representative to act as the primary point of contact with CSL.
CALLS FOR SCIENTIFIC PROPOSALS
CSL will work with nominated BD or Commercialisation representatives from participating research organisations and companies to seek scientific proposals that align with the focus areas of the 2026 Research Acceleration Initiative. Focus areas will be communicated with registered organisations via webinars and flyers ahead of online applications opening. Scientists who wish to apply will be invited to submit a 300-word online abstract outlining their proposal.
Online submission of abstracts will open in January 2026.
Online information sessions for scientists will be run in February 2026.
LIMITATIONS ON ABSTRACT SUBMISSIONS
There is no limit on the number of abstracts that registered research organisations or individual researchers can submit.
FUNDING
Successful applicants will receive up to $200,000 USD per year over two years (up to $400,000 USD in total) to accelerate translation of their research.
Funding is subject to successful execution of a research funding and option agreement between CSL and the partner organisation.